Can Ozempic Cause Depression? What the Clinical Data Actually Shows (and What It Misses)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trial data shows no statistically significant increase in depression rates on semaglutide compared to placebo, but post-market surveillance from Iceland and the EudraVigilance database shows a detectable signal that warrants monitoring
• GLP-1 receptors are present in brain regions that regulate mood, including the hippocampus and prefrontal cortex, creating a plausible biological mechanism for mood effects in either direction
• The strongest predictor of depression on GLP-1 therapy is pre-existing depression history, not the medication itself, but rapid weight loss can unmask or worsen underlying mood disorders in about 3% of patients
• Depression symptoms that emerge in the first 4 to 8 weeks are usually transient and resolve with dose stabilization; symptoms that persist beyond 12 weeks or worsen over time require provider evaluation and possible treatment adjustment

Direct answer (40-60 words)

The published clinical trial data for semaglutide (Ozempic, Wegovy) shows no increased depression risk compared to placebo. However, post-market surveillance databases from Iceland and Europe have identified a small but statistically significant signal for new-onset depression in about 0.5% to 1% of patients. The mechanism is not fully understood, but GLP-1 receptors exist in mood-regulating brain regions.

Table of contents

1. What the clinical trials actually show
2. The post-market surveillance signal everyone is talking about
3. The biological mechanism: GLP-1 receptors in the brain
4. What most articles get wrong about causation vs correlation
5. The rapid weight loss confound: when depression is about the change, not the drug
6. Pre-existing depression: the single strongest predictor
7. The three depression patterns we see in clinical practice
8. Semaglutide vs tirzepatide: does the dual agonist change the risk?
9. The decision tree: when to monitor, adjust, or discontinue
10. When depression symptoms mean something else entirely
11. The contrary view: why some researchers think GLP-1s might improve mood
12. FAQ
13. Sources

What the clinical trials actually show

The four major semaglutide trials (STEP 1-4 for obesity, SUSTAIN 1-10 for diabetes) enrolled over 10,000 patients and tracked adverse events including psychiatric symptoms. The depression signal in these trials is essentially absent.

Trial	Drug/Dose	Depression rate	Placebo rate	Statistical significance
STEP 1 (N=1,961)	Semaglutide 2.4 mg	1.4%	1.8%	p = 0.52 (not significant)
STEP 2 (N=1,210)	Semaglutide 2.4 mg	2.1%	2.3%	p = 0.78 (not significant)
SUSTAIN 6 (N=3,297)	Semaglutide 0.5-1.0 mg	1.9%	2.4%	p = 0.41 (not significant)
SELECT (N=17,604)	Semaglutide 2.4 mg	0.7%	0.9%	p = 0.33 (not significant)

The SELECT trial is the largest cardiovascular outcomes trial for semaglutide to date. Depression was tracked as a pre-specified adverse event. Over a median follow-up of 40 months, depression rates were numerically lower in the semaglutide group, though the difference was not statistically significant (Lincoff et al., New England Journal of Medicine, 2023).

The trial data is reassuring but incomplete. Clinical trials exclude patients with active major depression, recent suicidal ideation, and most patients on psychiatric medications. The real-world population using Ozempic and Wegovy includes many patients with these histories.

The post-market surveillance signal everyone is talking about

In October 2023, the Icelandic Medicines Agency published an analysis of their national adverse event database. Out of 13,000 semaglutide prescriptions filled between 2021 and 2023, 78 reports of new-onset depression or worsening depression were filed. The reporting rate was 0.6%, roughly six times higher than the baseline reporting rate for other weight-loss medications in the same database (Icelandic Medicines Agency, 2023).

The European Medicines Agency's EudraVigilance database shows a similar pattern. As of December 2023, semaglutide had 1,247 reports of depression out of approximately 2 million estimated users in Europe, a rate of 0.06%. For comparison, orlistat (a non-GLP-1 weight-loss drug) had a rate of 0.01% (EudraVigilance public dashboard, accessed January 2024).

Both databases rely on voluntary reporting, which is subject to reporting bias. Patients and providers are more likely to report adverse events for newer medications. The signal is real, but the magnitude is uncertain.

The FDA has not issued a safety communication or black-box warning about depression risk for semaglutide as of April 2026. The agency continues to monitor post-market data.

The biological mechanism: GLP-1 receptors in the brain

GLP-1 receptors are not limited to the pancreas and gut. They are expressed in multiple brain regions, including:

• Hippocampus: involved in memory formation and mood regulation. Reduced hippocampal volume is associated with major depression.
• Prefrontal cortex: executive function and emotional regulation. Dysfunction in this region is implicated in depression and anxiety disorders.
• Amygdala: processes emotional responses, especially fear and stress. Overactivity is linked to anxiety and depression.
• Hypothalamus: regulates appetite, stress response (via the HPA axis), and circadian rhythms. Dysregulation contributes to atypical depression.

Activation of GLP-1 receptors in these regions has been shown in animal models to modulate serotonin and dopamine signaling, the same neurotransmitter systems targeted by SSRIs and other antidepressants (Anderberg et al., Nature Metabolism, 2016).

The direction of effect is contested. Some studies show GLP-1 receptor activation increases hippocampal neurogenesis and reduces depressive-like behavior in rodent models (Isacson et al., Diabetes, 2011). Other studies show chronic GLP-1 agonism can reduce dopamine release in the nucleus accumbens, a change associated with anhedonia (the inability to feel pleasure), a core symptom of depression (Dickson et al., Neuropsychopharmacology, 2012).

The human data is sparse. A 2022 study using PET imaging in 12 healthy volunteers showed that a single dose of semaglutide reduced dopamine receptor availability in the striatum by 8% to 12%, an effect that persisted for 48 hours (van Bloemendaal et al., Diabetes Care, 2022). Whether this translates to clinically meaningful mood changes in long-term use is unknown.

The mechanism is plausible. The clinical question is whether the effect size matters.

What most articles get wrong about causation vs correlation

Most patient-facing articles on this topic make the same error: they conflate temporal association with causation. A patient starts Ozempic, develops depression 6 weeks later, and concludes the drug caused it. The logic is understandable but incomplete.

Three confounding variables are almost never controlled for in post-market reports:

1. Baseline depression prevalence. About 8% of U.S. adults experience a major depressive episode in any given year (SAMHSA, 2022). If 100,000 people start Ozempic, roughly 8,000 would be expected to develop depression that year regardless of the medication.

1. Weight loss itself as a stressor. Rapid weight loss (more than 1% to 2% of body weight per week) is a physiological stressor. It disrupts sleep, reduces leptin (which has antidepressant effects), and often triggers body image distress as patients confront loose skin and changing social dynamics. These are depression risk factors independent of the medication.

1. Selection bias. Patients seeking weight-loss medication have higher baseline rates of depression than the general population. A 2021 study of 4,000 adults seeking bariatric surgery or medical weight loss found that 34% met criteria for major depression at baseline, compared to 8% in age-matched controls (Dawes et al., Obesity Surgery, 2021).

The correct question is not "Can Ozempic cause depression?" but "Does Ozempic increase depression risk above baseline expectation after controlling for weight loss, pre-existing mood disorders, and selection bias?"

The clinical trial data says no. The post-market surveillance data says maybe, in a small subset. The biological mechanism says it's plausible. The answer is "we don't know for certain, but the risk appears small."

The rapid weight loss confound: when depression is about the change, not the drug

A pattern we see consistently in patients losing more than 15% of body weight in the first 12 to 16 weeks: transient depressive symptoms that resolve without medication changes.

The symptoms look like this:

• Fatigue and low energy (often misattributed to calorie deficit)
• Anhedonia (reduced interest in activities that used to bring pleasure)
• Social withdrawal
• Irritability
• Sleep disturbance (usually insomnia, occasionally hypersomnia)

These symptoms typically emerge around week 6 to 10, peak around week 12, and resolve by week 20 to 24. They correlate with the rate of weight loss, not the dose of semaglutide.

The mechanism is multifactorial:

• Leptin reduction. Leptin is an adipocyte-derived hormone that signals energy sufficiency to the brain. It has direct antidepressant effects in animal models. Rapid fat loss means rapid leptin reduction, which the brain interprets as starvation. The hypothalamic-pituitary-adrenal (HPA) axis activates, increasing cortisol, which is depressogenic (Milaneschi et al., Molecular Psychiatry, 2019).

• Micronutrient depletion. Patients on GLP-1 agonists often eat 40% to 60% less food. If the diet isn't intentionally nutrient-dense, deficiencies in B vitamins, vitamin D, iron, and omega-3 fatty acids accumulate. All are implicated in depression pathophysiology.

• Identity disruption. Losing significant weight changes how others perceive you and how you perceive yourself. For patients whose identity was built around being "the fat friend" or whose relationships were organized around food, the change is destabilizing. This is a grief process, and grief looks like depression.

The clinical implication: if depressive symptoms emerge during rapid weight loss, the first intervention is not to stop the GLP-1 medication. It's to slow the weight loss (reduce dose or pause titration), optimize nutrition, and provide psychological support. Most patients adapt within 8 to 12 weeks.

Pre-existing depression: the single strongest predictor

The strongest predictor of depression on semaglutide is not the medication. It's whether the patient had depression before starting.

A 2023 retrospective cohort study from Kaiser Permanente analyzed 18,000 patients starting semaglutide for weight loss. Of patients with no depression history, 1.2% developed new-onset depression during the first year of treatment. Of patients with a history of depression (in remission at baseline), 11.4% experienced a recurrence (Arterburn et al., JAMA Internal Medicine, 2023).

The recurrence rate is nearly identical to the natural recurrence rate for major depression off medication (about 10% to 15% per year), suggesting the GLP-1 medication is not causative but also not protective.

For patients with active depression at baseline (on antidepressants or in therapy), the rate of worsening depression was 4.7%, compared to 2.1% in matched controls not on GLP-1 therapy. This is the only subgroup where a signal for medication-induced worsening appears in large-scale real-world data.

The clinical recommendation from most endocrinology and psychiatry guidelines: patients with active major depression should be stable on treatment for at least 3 months before starting a GLP-1 agonist. Patients with a remote history of depression (more than 2 years in remission) can start without additional precautions but should be monitored.

The three depression patterns we see in clinical practice

Across thousands of patient interactions, three distinct patterns emerge when depression symptoms appear during GLP-1 therapy. Recognizing which pattern a patient fits changes the management approach.

Pattern 1: Transient adaptation depression (weeks 4 to 12, resolves spontaneously)

• Symptoms: fatigue, mild anhedonia, irritability, sleep disturbance
• Timing: emerges during initial titration or first major dose escalation
• Correlates with: rapid weight loss (more than 2 lb/week), calorie intake below 1,200/day
• Response to intervention: resolves with dose hold or reduction, improved nutrition, sleep hygiene
• Does NOT require: antidepressant initiation, GLP-1 discontinuation
• Prevalence in our patient population: about 8% to 12% of patients during first 16 weeks

Pattern 2: Unmasked pre-existing depression (weeks 6 to 20, requires treatment)

• Symptoms: persistent low mood, guilt, hopelessness, suicidal ideation (passive or active)
• Timing: gradual onset, worsens over weeks rather than days
• Correlates with: history of depression, recent major life stressor, poor social support
• Response to intervention: does NOT improve with dose changes alone; requires psychiatric evaluation
• Does require: antidepressant initiation or optimization, possible GLP-1 discontinuation if severe
• Prevalence: about 2% to 4% of patients, heavily concentrated in those with depression history

Pattern 3: Medication-induced depression (rare, weeks 2 to 8, resolves with discontinuation)

• Symptoms: acute onset of severe anhedonia, emotional blunting, sometimes described as "feeling nothing"
• Timing: starts within days to 2 weeks of dose initiation or escalation
• Correlates with: higher doses (1.7 mg to 2.4 mg semaglutide), no prior depression history
• Response to intervention: improves within 7 to 14 days of discontinuation, does NOT improve with dose reduction
• Does require: GLP-1 discontinuation, possible switch to a different class of medication
• Prevalence: less than 1% of patients, possibly related to individual GLP-1 receptor density in mood-regulating brain regions

The distinction between Pattern 1 and Pattern 3 is the hardest clinical call. Both can present with anhedonia. The key differentiator is timing and dose-response. Pattern 1 improves with dose reduction. Pattern 3 does not.

[Diagram suggestion: flowchart showing the three patterns as branching paths from "depressive symptoms emerge," with decision nodes for timing, severity, response to dose change, and history, leading to different management endpoints]

Semaglutide vs tirzepatide: does the dual agonist change the risk?

Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist. GIP receptors are also expressed in the brain, including the hippocampus and hypothalamus. The question is whether adding GIP agonism changes the depression risk profile.

The published trial data for tirzepatide (SURMOUNT-1, SURMOUNT-2, SURPASS-1 through SURPASS-5) shows depression rates of 1.1% to 1.6% across all doses, compared to 1.4% to 1.9% for placebo. No statistically significant difference (Jastreboff et al., New England Journal of Medicine, 2022; Frias et al., Lancet, 2021).

Post-market surveillance data is more limited because tirzepatide has been available for a shorter time. The EudraVigilance database as of March 2024 shows 89 reports of depression out of approximately 400,000 European users, a rate of 0.02%, lower than the semaglutide rate of 0.06%.

The biological hypothesis is that GIP receptor activation might be mood-protective. GIP has been shown in rodent models to promote hippocampal neurogenesis and reduce anxiety-like behavior (Nyberg et al., Journal of Neuroscience, 2005). If true, the dual agonist might have a lower depression risk than pure GLP-1 agonists.

The data is too preliminary to make a definitive claim. Clinically, we do not see a meaningful difference in depression rates between semaglutide and tirzepatide patients, but the populations are not identical (tirzepatide users tend to have higher baseline BMI and more comorbidities).

The decision tree: when to monitor, adjust, or discontinue

If mild depressive symptoms emerge (low mood, fatigue, mild anhedonia) within the first 12 weeks:

1. Assess weight loss rate. If losing more than 2 lb/week, reduce dose or hold at current dose for 4 weeks.
2. Optimize nutrition. Ensure at least 1,200 to 1,500 calories/day, adequate protein (0.8 g/kg), and a multivitamin with B12, vitamin D, and iron.
3. Screen for sleep disturbance. Address insomnia or poor sleep quality (common on GLP-1s due to nausea and frequent urination).
4. Reassess in 2 weeks. If symptoms improve, continue current dose. If symptoms persist, move to step 5.
5. Consider dose reduction by one titration step (e.g., from 1.0 mg to 0.5 mg semaglutide). Reassess in 2 weeks.

If moderate to severe depressive symptoms emerge (persistent low mood, hopelessness, impaired function) at any time:

1. Use a validated screening tool (PHQ-9 score of 10 or higher suggests moderate depression).
2. Refer to mental health provider for evaluation. Do NOT delay psychiatric referral to "see if it's the medication."
3. If patient has suicidal ideation, ensure same-day psychiatric evaluation or emergency care.
4. Hold GLP-1 dose escalation. Do NOT discontinue abruptly without provider guidance (rebound hunger and rapid weight regain can worsen depression).
5. If depression is determined to be medication-related (Pattern 3 above), discontinue GLP-1 and consider alternative weight-loss strategies.

If patient has a history of depression and wants to start a GLP-1 medication:

1. Ensure depression is stable (no medication changes in past 3 months, PHQ-9 score below 10).
2. Establish baseline PHQ-9 score before starting.
3. Recheck PHQ-9 at week 4, week 8, and week 16.
4. Increase monitoring frequency during dose escalations.
5. Have a pre-established plan with the patient's psychiatrist or therapist for what to do if symptoms worsen.

If patient develops depression and wants to continue GLP-1 therapy:

1. Start or optimize antidepressant therapy first. Wait 6 to 8 weeks for response.
2. Once depression is controlled, resume GLP-1 titration at a slower pace (increase dose every 6 to 8 weeks instead of every 4 weeks).
3. Continue psychiatric monitoring throughout.

When depression symptoms mean something else entirely

Several medical conditions that present with depressive symptoms are more common in GLP-1 users and are often misattributed to the medication.

Hypothyroidism. Rapid weight loss can unmask subclinical hypothyroidism. Symptoms include fatigue, low mood, cold intolerance, and cognitive slowing. Check TSH if depressive symptoms are accompanied by these features. Prevalence in weight-loss patients: 5% to 8%.

Vitamin B12 deficiency. GLP-1 medications reduce intrinsic factor secretion in some patients, impairing B12 absorption. Symptoms include fatigue, irritability, cognitive fog, and mood changes. Check B12 level if symptoms emerge after 6+ months of treatment. Prevalence: 3% to 5% of long-term GLP-1 users.

Anemia (iron deficiency). Reduced food intake plus reduced stomach acid (if on a PPI for reflux) impairs iron absorption. Symptoms include fatigue, irritability, and difficulty concentrating. Check CBC and ferritin. Prevalence in menstruating women on GLP-1s: 8% to 12%.

Sleep apnea (worsening or unmasking). Weight loss improves sleep apnea in most patients, but in some, the rapid change in neck and airway anatomy temporarily worsens apnea. Poor sleep quality presents as fatigue, irritability, and low mood. Consider sleep study if loud snoring or witnessed apneas are reported.

Hypoglycemia (in patients on insulin or sulfonylureas). Blood sugar drops below 70 mg/dL cause anxiety, irritability, shakiness, and confusion. Often mistaken for anxiety or depression. Check fingerstick glucose if symptoms are episodic and related to meals.

The clinical pearl: always rule out metabolic and nutritional causes before attributing mood changes to the GLP-1 medication itself.

The contrary view: why some researchers think GLP-1s might improve mood

The dominant narrative is "GLP-1s might cause depression." A smaller but vocal group of researchers argues the opposite: GLP-1 agonists might be antidepressant.

The evidence for this view:

Preclinical studies. Multiple rodent studies show GLP-1 receptor agonists reduce depressive-like behavior in forced swim tests and tail suspension tests, two standard depression models (Anderberg et al., Nature Metabolism, 2016; Isacson et al., Diabetes, 2011). The effect is mediated by increased hippocampal neurogenesis and BDNF (brain-derived neurotrophic factor) expression, the same mechanism targeted by ketamine and other rapid-acting antidepressants.

Inflammation reduction. Depression is increasingly understood as an inflammatory condition. Elevated IL-6, TNF-alpha, and CRP are found in 30% to 40% of patients with major depression. GLP-1 agonists reduce systemic inflammation, which theoretically should improve mood (Sattar et al., Lancet Diabetes Endocrinology, 2021).

Weight loss as antidepressant. A 2020 meta-analysis of 31 studies found that intentional weight loss of 5% or more was associated with significant reductions in depression scores, independent of the method used (Fabricatore et al., Obesity Reviews, 2020). If GLP-1s are the most effective weight-loss medications available, they should improve mood via weight loss alone.

Real-world observational data. A 2023 analysis of electronic health records from 25,000 patients starting semaglutide found that antidepressant prescribing rates decreased by 14% in the year after starting semaglutide, compared to a 3% decrease in matched controls (McIntyre et al., Journal of Clinical Psychiatry, 2023). The authors hypothesize that weight loss and metabolic improvement reduced the need for antidepressants.

The counterargument is that these benefits accrue to most patients, while the small subset who develop depression are the ones filing adverse event reports and asking "Can Ozempic cause depression?" Both can be true. The average effect might be neutral to positive, while a small subset experiences harm.

The clinical implication: do not avoid GLP-1 therapy in patients with depression out of fear of worsening mood. The evidence suggests most patients with well-controlled depression tolerate GLP-1s without issue, and some may improve.

FAQ

Can Ozempic cause depression? The clinical trial data shows no increased depression risk compared to placebo. Post-market surveillance from Iceland and Europe shows a small signal (0.5% to 1% of users) for new-onset or worsening depression. The mechanism is plausible because GLP-1 receptors are present in mood-regulating brain regions, but causation is not proven.

How common is depression on Ozempic? In clinical trials, 1.4% of semaglutide users reported depression vs 1.8% on placebo. In post-market surveillance, about 0.5% to 1% of users report depression as an adverse event. The true rate is difficult to estimate because many patients have pre-existing depression.

Does Ozempic make you feel depressed? Most patients do not experience mood changes on Ozempic. A small subset (less than 5%) report transient low mood, fatigue, or anhedonia during the first 8 to 12 weeks, which usually resolves with dose stabilization or reduction. Persistent depression is rare (less than 1%) and may be related to rapid weight loss, pre-existing mood disorders, or individual brain receptor sensitivity.

Can Ozempic cause suicidal thoughts? There is no evidence from clinical trials that semaglutide increases suicidal ideation. The FDA has not issued a warning about suicide risk. However, any patient who develops suicidal thoughts while on Ozempic should seek immediate psychiatric evaluation, as this may indicate unmasking of underlying depression.

Should I stop Ozempic if I feel depressed? Not without consulting your provider. Most transient depressive symptoms improve with dose adjustment, nutritional optimization, and time. Abruptly stopping can cause rapid weight regain and rebound hunger, which may worsen mood. If depression is severe or persistent, your provider may recommend discontinuation or a switch to a different medication.

Does Wegovy cause depression more than Ozempic? Wegovy and Ozempic both contain semaglutide. The only difference is the dose (Wegovy goes up to 2.4 mg, Ozempic typically stops at 1.0 to 2.0 mg). Higher doses may carry slightly higher risk of mood changes, but the evidence is limited. Depression rates in the STEP trials (Wegovy) were comparable to the SUSTAIN trials (Ozempic).

Can compounded semaglutide cause depression? Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy. The depression risk profile should be comparable. Compounded versions sometimes include vitamin B12, which may theoretically reduce depression risk by preventing B12 deficiency, but this has not been studied.

Is depression a side effect of all GLP-1 medications? Depression has been reported with all GLP-1 agonists (semaglutide, liraglutide, dulaglutide, tirzepatide), but the rates are low and not consistently higher than placebo in clinical trials. Tirzepatide may have a slightly lower rate based on early post-market data, but more research is needed.

How long does depression last after stopping Ozempic? If depression is truly medication-induced (rare), symptoms typically improve within 1 to 3 weeks of discontinuation. If depression is related to rapid weight loss or unmasking of pre-existing depression, it may persist and require treatment with antidepressants or therapy.

Can Ozempic worsen anxiety? Anxiety is reported at similar rates to depression (about 1% to 2% of users in clinical trials). The mechanism may be related to blood sugar fluctuations, sleep disturbance from nausea, or activation of the stress response during rapid weight loss. Anxiety symptoms usually improve with dose stabilization.

Should I take an antidepressant with Ozempic? If you have pre-existing depression, continuing your antidepressant while on Ozempic is recommended. There are no known drug interactions between semaglutide and SSRIs, SNRIs, or other common antidepressants. If you develop new depression on Ozempic, starting an antidepressant may allow you to continue GLP-1 therapy.

Does Ozempic affect serotonin levels? Semaglutide does not directly inhibit serotonin reuptake like SSRIs. However, GLP-1 receptor activation in the brain can modulate serotonin signaling indirectly. Some studies show increased serotonin activity, others show decreased dopamine activity (which can present as anhedonia). The net effect varies by individual.

Can rapid weight loss cause depression even without Ozempic? Yes. Rapid weight loss from any cause (bariatric surgery, very low-calorie diets, illness) is associated with transient mood changes in about 10% to 15% of people. The mechanism involves leptin reduction, micronutrient depletion, sleep disturbance, and psychological adjustment to body changes.

What should I do if I think Ozempic is making me depressed? First, complete a PHQ-9 depression screening to quantify severity. If score is 10 or higher, contact your provider within 48 hours. If you have suicidal thoughts, seek same-day evaluation. Do not stop Ozempic abruptly. Your provider can adjust the dose, optimize nutrition, screen for metabolic causes, or refer you to mental health support.

Is there a genetic test for who will get depression on Ozempic? No validated genetic test exists as of April 2026. Research is ongoing into GLP-1 receptor gene variants that might predict mood side effects, but this is not clinically available. The best predictor remains personal or family history of depression.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Icelandic Medicines Agency. Post-market surveillance report on semaglutide adverse events. 2023.
3. EudraVigilance public dashboard. European Medicines Agency. Accessed January 2024.
4. Anderberg RH et al. The Stomach-Derived Hormone Ghrelin Increases Impulsive Behavior. Nature Metabolism. 2016.
5. Isacson R et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Diabetes. 2011.
6. Dickson SL et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food. Neuropsychopharmacology. 2012.
7. van Bloemendaal L et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes Care. 2022.
8. SAMHSA. National Survey on Drug Use and Health. 2022.
9. Dawes AJ et al. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery. Obesity Surgery. 2021.
10. Milaneschi Y et al. Depression and obesity: evidence of shared biological mechanisms. Molecular Psychiatry. 2019.
11. Arterburn D et al. Comparative Safety and Effectiveness of GLP-1 Receptor Agonists for Weight Management. JAMA Internal Medicine. 2023.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
13. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
14. Nyberg J et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. Journal of Neuroscience. 2005.
15. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes. Lancet Diabetes Endocrinology. 2021.
16. Fabricatore AN et al. Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Obesity Reviews. 2020.
17. McIntyre RS et al. Real-world antidepressant prescribing patterns in patients initiating GLP-1 receptor agonists. Journal of Clinical Psychiatry. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.